Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial.

MLA

Fiorillo, Loretta, et al. “Efficacy and Safety of Apremilast in Pediatric Patients with Moderate-to-Severe Plaque Psoriasis: 16-Week Results from SPROUT, a Randomized Controlled Trial.” Journal of the American Academy of Dermatology, vol. 90, no. 6, June 2024, pp. 1232–39. EBSCOhost, https://doi.org/10.1016/j.jaad.2023.11.068.

APA

Fiorillo, L., Becker, E., de Lucas, R., Belloni-Fortina, A., Armesto, S., Elewski, B., Maes, P., Oberoi, R. K., Paris, M., Zhang, W., Zhang, Z., & Arkin, L. (2024). Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial. Journal of the American Academy of Dermatology, 90(6), 1232–1239. https://doi.org/10.1016/j.jaad.2023.11.068

Chicago

Fiorillo, Loretta, Emily Becker, Raul de Lucas, Anna Belloni-Fortina, Susana Armesto, Boni Elewski, Peter Maes, et al. 2024. “Efficacy and Safety of Apremilast in Pediatric Patients with Moderate-to-Severe Plaque Psoriasis: 16-Week Results from SPROUT, a Randomized Controlled Trial.” Journal of the American Academy of Dermatology 90 (6): 1232–39. doi:10.1016/j.jaad.2023.11.068.